We are live on
!
Find out more
Balyasny Asset Management Portfolio holdings
AUM
$77.1B
1-Year Est. Return
42.89%
This Fund
S&P 500
This Quarter
Est. Return
+7.96%
1 Year Est. Return
+42.89%
3 Year Est. Return
+126.29%
5 Year Est. Return
+172.74%
10 Year Est. Return
+1,026.86%
AUM
$78.8B
AUM Growth
-$135M
(-0.17%)
Cap. Flow
-$4.13B
Cap. Flow
% of AUM
-5.25%
Top 10 Holdings %
Top 10 Hldgs %
14.64%
Holding
3,669
New
809
Increased
1,002
Reduced
1,102
Closed
643
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$807M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$497M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$390M |
| 4 |
Kenvue
KVUE
|
+$379M |
| 5 |
Broadcom
AVGO
|
+$324M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$409M |
| 2 |
Visa
V
|
+$354M |
| 3 |
Advanced Micro Devices
AMD
|
+$328M |
| 4 |
Meta Platforms (Facebook)
META
|
+$317M |
| 5 |
Lockheed Martin
LMT
|
+$316M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 11.61% |
| 2 | Consumer Discretionary | 9.64% |
| 3 | Healthcare | 8.17% |
| 4 | Industrials | 8.1% |
| 5 | Financials | 8.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2651
Ginkgo Bioworks
DNA
$486M
| $316K | ﹤0.01% |
37,977
-59,941
| -61% | -$645K |
|
2652
CALL
Zeta Global
ZETA
$7.17B
| $315K | ﹤0.01% |
+15,500
| New | +$290K |
|
2653
PUT
Illumina
ILMN
$29.1B
| $315K | ﹤0.01% |
+2,400
| New | +$282K |
|
2654
Centrus Energy
LEU
$3.69B
| $314K | ﹤0.01% |
1,293
-11,661
| -90% | -$3.52M |
|
|
CCCX
2655
CALL
DELISTED
Churchill Capital Corp X
CCCX
| $314K | ﹤0.01% |
+20,100
| New | +$338K |
|
2656
WaFd
WAFD
$2.79B
| $311K | ﹤0.01% |
9,720
-1,363
| -12% | -$42.1K |
|
2657
Embecta
EMBC
$269M
| $311K | ﹤0.01% |
26,204
+6,401
| +32% | +$84.4K |
|
2658
PUT
Marriott International
MAR
$92.5B
| $310K | ﹤0.01% |
1,000
-13,600
| -93% | -$3.89M |
|
2659
AMERISAFE
AMSF
$517M
| $309K | ﹤0.01% |
8,054
+2,847
| +55% | +$115K |
|
2660
Banner Corp
BANR
$2.5B
| $308K | ﹤0.01% |
4,909
+386
| +9% | +$24.4K |
|
2661
NVR
NVR
$16.8B
| $306K | ﹤0.01% |
+42
| New | +$314K |
|
2662
QuantumScape Corp
QS
$3.92B
| $304K | ﹤0.01% |
29,200
-198,804
| -87% | -$2.74M |
|
2663
Babcock & Wilcox
BW
$1.46B
| $304K | ﹤0.01% |
+47,984
| New | +$237K |
|
2664
Titan Machinery
TITN
$431M
| $303K | ﹤0.01% |
+20,132
| New | +$324K |
|
|
SW
2665
Smurfit Westrock
SW
$25.8B
| $302K | ﹤0.01% |
+7,815
| New | +$298K |
|
|
ACP
2666
abrdn Income Credit Strategies Fund
ACP
$646M
| $302K | ﹤0.01% |
+55,755
| New | +$307K |
|
2667
Church & Dwight Co
CHD
$24B
| $301K | ﹤0.01% |
3,594
-707,676
| -99% | -$60.5M |
|
2668
PUT
Canadian Natural Resources
CNQ
$98.1B
| $301K | ﹤0.01% |
+8,900
| New | +$289K |
|
2669
Fox Class B
FOX
$23.5B
| $301K | ﹤0.01% |
+4,629
| New | +$270K |
|
2670
Mesa Laboratories
MLAB
$631M
| $298K | ﹤0.01% |
3,792
-180
| -5% | -$13.7K |
|
2671
Riley Exploration Permian
REPX
$796M
| $297K | ﹤0.01% |
+11,261
| New | +$299K |
|
2672
Capital Southwest
CSWC
$1.6B
| $297K | ﹤0.01% |
13,410
-14,433
| -52% | -$305K |
|
2673
Stoke Therapeutics
STOK
$2.13B
| $296K | ﹤0.01% |
+9,340
| New | +$281K |
|
|
UNIT
2674
Uniti Group
UNIT
$2.31B
| $296K | ﹤0.01% |
42,231
-87,188
| -67% | -$552K |
|
2675
Zimmer Biomet
ZBH
$18.7B
| $296K | ﹤0.01% |
+3,287
| New | +$312K |
|
Similar funds
CBU
BC
Balyasny Asset Management's Q4 2025 Portfolio in Review
As of Q4 2025, Balyasny Asset Management held 3,669 positions worth $78.8B, down 0.17% from $78.9B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Balyasny Asset Management withdrew a net $4.13B in Q4 2025, closing 643 positions and reducing 1,102 holdings. Its most notable exit was Mr. Cooper, an estimated $277M position sold in full.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 12% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Balyasny Asset Management opened a new position in Avidity Biosciences worth $436M.
- Balyasny Asset Management's largest Q4 2025 buy was Avidity Biosciences: 6,040,590 shares worth $436M.
- Balyasny Asset Management added most to Amazon in Q4 2025, an estimated $807M increase.
- Balyasny Asset Management's biggest Q4 2025 reduction was Apple, cutting an estimated $409M.
- Balyasny Asset Management fully exited Mr. Cooper in Q4 2025, selling an estimated $277M.
- Balyasny Asset Management's ten largest holdings make up 15% of its $78.8B portfolio in Q4 2025.
- Balyasny Asset Management opened 809 new positions and closed 643 in Q4 2025.
- Balyasny Asset Management's portfolio value fell 0.17% quarter-over-quarter to $78.8B.
Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.